2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections

A compound of the formula

• wherein
• R1 is NO2, NH2, NHOR4, COOR4, CONR5R6, or CHO;
• R2 is halogen, SO2NR5R6, lower alkoxy, COOR4, CONR5R6, CHO, OCF3, or mono-, di- or trifluoromethyl;
• R3 is a saturated or unsaturated, halogenated or unhalogenated, linear, branched or cyclic alkyl having 3-12 carbon atoms, where optionally one or two of methylene groups when present are substituted by O, S or NR4, or
• wherein
• X is saturated or unsaturated, linear or branched aliphatic radical having 1-6 carbon atoms;
• Y is O, S, or NR4;
• Z is direct bond, linear or branched aliphatic radical having 1-3 carbon atoms;
• Q is phenyl, naphtyl, pyridyl, chinolyl, pyrazinyl, pyrimidyl, pyrazolyl, triazinyl, imidazolyl, furanyl, or thienyl and optionally, where one to three hydrogen atoms are substituted by a R7 group;
• R4 is H or C1-3-alkyl;
• n=0, 1, 2, 3, or 4
• R5 and R6 are, independently each from other selected from H, C1-4-alkyl, OC1-4-alkyl, halogen, COOR5, CONR6R7, OCF3, CF3 or CN;
• R7 group is halogen, saturated or unsaturated, linear or branched aliphatic radical having 1-3 carbon atoms, SO2NR5R6, lower alkoxy, COOR4, CONR5R6, CHO, OCF3, mono-, di- or trifluoromethy, or phenyl,
• and/or a pharmaceutically acceptable salt thereof.